Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.

Matsuoka, Akihito; Tanibuchi, Masaki; Yamazaki, Ieharu; Taoka, Teruhisa

Matsuoka, Akihito; Tanibuchi, Masaki; Yamazaki, Ieharu; Taoka, Teruhisa.

Afiliação

Matsuoka A; Department of Hematology, Sakaide City Hospital, 3-1-2 Kotobuki-Town, Sakaide, Kagawa, 762-8550, Japan. makihito625@gmail.com.
Tanibuchi M; Department of Laboratory Medicine, Sakaide City Hospital, Sakaide, Japan.
Yamazaki I; Department of Electron Microscope, BML Research Institute Inc., Saitama, Japan.
Taoka T; Department of Molecular Pathology, Tokyo Medical University, School of Medicine, Tokyo, Japan.

Int J Hematol ; 115(6): 852-859, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35275354

Assuntos

Leucemia Mieloide Aguda; Síndromes Mielodisplásicas; Cariótipo Anormal; Idoso; Antimetabólitos Antineoplásicos/uso terapêutico; Azacitidina/uso terapêutico; Eritroblastos; Humanos; Leucemia Mieloide Aguda/tratamento farmacológico; Leucemia Mieloide Aguda/genética; Síndromes Mielodisplásicas/tratamento farmacológico; Prognóstico

Palavras-chave

Azacitidine; CD41/cyCD41; Erythroblast predominance; Myelodysplastic syndromes; Prognostic analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google